Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study
-
Published:2021-10-28
Issue:
Volume:
Page:
-
ISSN:0770-3198
-
Container-title:Clinical Rheumatology
-
language:en
-
Short-container-title:Clin Rheumatol
Author:
Su Jinmei, Li Mengtao, He Lan, Zhao Dongbao, Wan Weiguo, Liu Yi, Xu Jianhua, Xu Jian, Liu Huaxiang, Jiang Lindi, Wu Huaxiang, Zuo Xiaoxia, Huang Cibo, Liu Xiumei, Li Fen, Zhang Zhiyi, Liu Xiangyuan, Dong Lingli, Li Tianwang, Chen Haiying, Li Jingyang, He Dongyi, Lu Xin, Huang Anbin, Tao Yi, Wang Yanyan, Zhang Zhuoli, Wei Wei, Li Xiaofeng, Zeng XiaofengORCID
Abstract
Abstract
Objective
The equivalence of the biosimilar HS016 to adalimumab (Humira) for the treatment of active ankylosing spondylitis (AS) patients has been previously validated. The aim was to compare the efficacy of HS016 and adalimumab in stratified subgroups at different time points using Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) and short form 36 (SF-36) questionnaires.
Methods
We carried out a multicenter, randomized, double-blind, parallel, positive control, phase 3 trial of patients with active AS. They were selected randomly to be subcutaneously administered 40 mg HS016 or adalimumab every 2 weeks for a total treatment period of 24 weeks in a 2:1 ratio. A health surveys were used to assess mental and physical improvements of patients as well as other factors.
Results
HAQ-S revealed that changes in scores from baseline in both groups were time dependent until 14 weeks and that during the first 4 weeks of treatment the changes declined rapidly. The SF-36 health survey revealed that both HS016 and adalimumab produced rapid beneficial effects against AS during the first 2 weeks of therapy, which gradually declined between 2 and 12 weeks and flattened out after 12 weeks until 24 weeks.
Conclusion
This trial demonstrated that both HS016 and adalimumab produced rapid improvements in symptoms during the first 2 weeks of treatment. These findings suggest that HS016 is an alternative economical treatment for Chinese AS patients producing a rapid amelioration of symptoms, aiding them to recover their lifestyle satisfaction.
Trial registration
http://www.chictr.org.cn/enindex.aspx, ChiCTR1900022520, retrospectively registered.
Key points
• HS016 and adalimumab produced rapid AS symptom improvements during the first 2 weeks followed by a slowdown of improvements until week 4 with afterwards few improvements evaluated by HAQ-S
• The improvements according to the short form of the 36 (SF-36) questionnaires revealed similar trends as for HAQ-S
• There was no significant difference in HAQ-S and SF-36 scores between HS016 and adalimumab
Funder
Chinese National Key Technology R&D Program, Ministry of Science and Technology Medicine and Health Technology Innovation Project, Chinese Academy of Medical Sciences zhejiang hisun pharmaceutical co., ltd
Publisher
Springer Science and Business Media LLC
Subject
General Medicine,Rheumatology
Reference25 articles.
1. Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X, Qiu G, Cao X, Weng X (2019) Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res 7(1):22. https://doi.org/10.1038/s41413-019-0057-8 2. Boonen A (2002) Socioeconomic consequences of ankylosing spondylitis. Clin Exp Rheumatol 20(6 Suppl 28):S23-26 3. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483 4. Yang X, Fan D, Xia Q, Wang M, Zhang X, Li X, Cai G, Wang L, Xin L, Xu S, Pan F (2016) The health-related quality of life of ankylosing spondylitis patients assessed by SF-36: a systematic review and meta-analysis. Qual Life Res 25(11):2711–2723. https://doi.org/10.1007/s11136-016-1345-z 5. Law L, Beckman Rehnman J, Deminger A, Klingberg E, Jacobsson LTH, Forsblad-d’Elia H (2018) Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex. Arthritis Res Ther 20(1):284. https://doi.org/10.1186/s13075-018-1784-8
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|